Holen Sie sich die Stockscreener-App
65.63
0.12%
-0.1663
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.80
Offen:
$66.43
24-Stunden-Volumen:
189.77K
Relative Volume:
0.11
Marktkapitalisierung:
$8.16B
Einnahmen:
$88.04M
Nettoeinkommen (Verlust:
$-784.96M
KGV:
-10.05
EPS:
-6.5335
Netto-Cashflow:
$-534.82M
1W Leistung:
+0.54%
1M Leistung:
+6.52%
6M Leistung:
+20.01%
1J Leistung:
+73.82%
1-Tages-Spanne:
$64.99
$66.43
1-Wochen-Bereich:
$63.97
$67.04
52-Wochen-Spanne:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.65 | 8.17B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
436.21 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.84 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
792.33 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.23 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.80 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $229,915 of company stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $229,915 of company stock - Investing.com
Cytokinetics (CYTK) EVP sells 3,500 shares after option exercise - Stock Titan
Cytokinetics to Announce First Quarter Results on May 5, 2026 - Yahoo Finance
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics Inc stock (US2328281044): Does its cardiac muscle inhibitor pipeline now become the tur - AD HOC NEWS
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Cytokinetics awards equity grants to 33 new hires under Nasdaq rule - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: A 39% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up - TipRanks
Cytokinetics Incorporated : 2025 Annual Report of 2025 - marketscreener.com
[DEF 14A] CYTOKINETICS INC Definitive Proxy Statement - Stock Titan
Can Myqorzo Drive Growth for Cytokinetics Amid Competition? - Yahoo Finance
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cytokinetics Insider Sold Shares Worth $491,783, According to a Recent SEC Filing - Moomoo
Massachusetts Financial Services Co. MA Cuts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Insider Sell: Andrew Callos Sells 7,449 Shares of Cytokinetics I - GuruFocus
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares, retains large stake - Stock Titan
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock - Investing.com
Director at CYTOKINETICS (CYTK) receives 95-share equity grant in lieu of cash - Stock Titan
Cytokinetics EVP Callos sells $491k in stock By Investing.com - Investing.com India
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock By Investing.com - Investing.com South Africa
Cytokinetics (NASDAQ: CYTK) director receives 95-share equity grant - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) director receives 191-share equity grant as retainer - Stock Titan
Cytokinetics EVP Callos sells $491k in stock - Investing.com
Andrew Callos Sells 7,449 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
CYTOKINETICS (CYTK) EVP Andrew Callos sells 7,449 shares in open market - Stock Titan
Andrew Callos sells via 10b5-1; CYTK (NASDAQ: CYTK) insider filings - Stock Titan
Cytokinetics Incorporated : Read Our 2025 Report - marketscreener.com
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference - MarketBeat
Cytokinetics Inc stock (US2328281044): Does cardiac muscle therapy execution now define its biotech - AD HOC NEWS
Fed Watch: Is Cytokinetics Incorporated undervalued by DCF analysisSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
CYTK Analyst Rating: Wells Fargo Initiates Overweight April 2026 - Meyka
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Q1 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc at JMP Securities Life Sciences Conference Transcript - GuruFocus
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Earnings Transcripts - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock News, Headlines & Updates - GuruFocus
Market Review: What are the future prospects of Cytokinetics IncorporatedAnalyst Downgrade & Real-Time Price Movement Reports - baoquankhu1.vn
Wells Fargo initiates coverage of Cytokinetics (CYTK) with overweight recommendation - MSN
CYTK Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Momentum Shift: Is Cytokinetics Incorporated stock heavily shortedWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
Risk Recap: Will Cytokinetics Incorporated stock go up in YEAR2026 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Cytokinetics Inc (HAM:KK3A) Valuation: Possible Value Trap, Think Twice - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Cytokinetics Inc (HAM:KK3A) Stock Today? - GuruFocus
Cytokinetics Inc Stock Operating Data - GuruFocus
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Apr 21 '26 |
Sale |
65.69 |
3,500 |
229,915 |
153,902 |
| Callos Andrew | EVP, Chief Commercial Officer |
Apr 15 '26 |
Sale |
66.02 |
7,449 |
491,783 |
58,555 |
| Blum Robert I | President & CEO |
Apr 15 '26 |
Sale |
65.38 |
7,500 |
490,350 |
415,330 |
1.40%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):